PMID- 17998285
OWN - NLM
STAT- MEDLINE
DCOM- 20080318
LR  - 20200203
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 19
IP  - 2
DP  - 2008 Feb
TI  - Serum HER2 extracellular domain predicts an aggressive clinical outcome and 
      biological PSA response in hormone-independent prostate cancer patients treated 
      with docetaxel.
PG  - 269-75
AB  - BACKGROUND: Human epidermal growth factor receptor 2 (HER2) overexpression has 
      been linked to hormone-independent prostate cancer (HIPC) progression. Its 
      clinical value and correlation with therapy is not defined. PATIENTS AND METHODS: 
      Patients with HIPC treated with docetaxel (Taxotere) were prospectively tested 
      for serum HER2 extracellular domain (ECD) by immunoanalysis. HER2 was determined 
      by immunohistochemistry and fluorescence in situ hybridization (FISH) in tumor 
      samples. RESULTS: Sixty-nine patients were included. Twenty-four (34.8%) patients 
      had high HER2 ECD (>15 ng/ml). Prostate-specific antigen (PSA) response was 58% 
      for patients with low HER2 ECD and 36% for patients with high HER2 ECD (P = 
      0.046). HER2 ECD levels were an independent prognostic factor for time to PSA 
      progression [hazard ratio (HR) 2.82; 95% confidence interval (CI) 1.22-6.50; P = 
      0.015] and overall survival (HR 3.24; 95% CI 1.38-7.59; P = 0.007). Tissue 
      samples from 17 patients were tested for HER2. Patients with negative HER2 tissue 
      expression had lower HER2 ECD levels (median 10.5 +/- 2.7 versus 30.5 +/- 24.8 
      ng/ml; P = 0.016). FISH was negative in all samples. CONCLUSIONS: High HER2 ECD 
      levels in serum are associated with a worst clinical outcome of HIPC patients 
      treated with docetaxel.
FAU - Domingo-Domenech, J
AU  - Domingo-Domenech J
AD  - Department of Medical Oncology and Laboratory of Experimental Oncology, Institut 
      Clinic de Malalties Hemato-Oncologiques, Barcelona, Spain.
FAU - Fernandez, P L
AU  - Fernandez PL
FAU - Filella, X
AU  - Filella X
FAU - Martinez-Fernandez, A
AU  - Martinez-Fernandez A
FAU - Molina, R
AU  - Molina R
FAU - Fernandez, E
AU  - Fernandez E
FAU - Alcaraz, A
AU  - Alcaraz A
FAU - Codony, J
AU  - Codony J
FAU - Gascon, P
AU  - Gascon P
FAU - Mellado, B
AU  - Mellado B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071112
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Hormonal/adverse effects/therapeutic use
MH  - Biomarkers, Tumor/*blood
MH  - Disease Progression
MH  - Docetaxel
MH  - Drug Resistance, Neoplasm
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Prostate-Specific Antigen/*blood/drug effects
MH  - Prostatic Neoplasms/*blood/*drug therapy/mortality/pathology
MH  - Receptor, ErbB-2/*blood
MH  - Survival Analysis
MH  - Taxoids/*therapeutic use
MH  - Treatment Outcome
EDAT- 2007/11/14 09:00
MHDA- 2008/03/19 09:00
CRDT- 2007/11/14 09:00
PHST- 2007/11/14 09:00 [pubmed]
PHST- 2008/03/19 09:00 [medline]
PHST- 2007/11/14 09:00 [entrez]
AID - S0923-7534(19)41344-6 [pii]
AID - 10.1093/annonc/mdm490 [doi]
PST - ppublish
SO  - Ann Oncol. 2008 Feb;19(2):269-75. doi: 10.1093/annonc/mdm490. Epub 2007 Nov 12.